Bardi M, Arnoldi E, Pizzocchero G, Pezzica E, Mattioni D, Perotti M
Department of Gynecology and Obstetrics, S. Isidoro Hospital Trescore Balneario, Bergamo.
Eur J Gynaecol Oncol. 1994;15(5):393-5.
This concerns a 57 year old woman operated on in 1988 for a left radical mastectomy due to ductal breast carcinoma and subsequently treated with chemotherapy and Tamoxifen adjuvant. In 1990 a laparo-hystero-oophorectomy was carried out due to uterine fibromas. The woman continued taking Tamoxifen. Two years later a pelvic regeneration appeared, resulting in endometriosis, site of adenomatose hyperplasia and of endometrioid carcinoma GI. This furthermore confirms the importance of a gynecological follow-up for all women treated with Tamoxifen adjuvant therapy.
这是一位57岁女性的病例，她于1988年因乳腺导管癌接受了左侧根治性乳房切除术，随后接受了化疗和他莫昔芬辅助治疗。1990年，因子宫纤维瘤进行了腹腔镜子宫卵巢切除术。该女性继续服用他莫昔芬。两年后出现盆腔再生，导致子宫内膜异位症，这是腺瘤样增生和子宫内膜样癌GI的发病部位。这进一步证实了对所有接受他莫昔芬辅助治疗的女性进行妇科随访的重要性。
